Tools
Tools
McPhillie, Martin, Zhou, Ying, Hickman, Mark, Gordon, James, Weber, Christopher R., Li, Qigui, Lee, Patty, Amporndana, Kangsa, Johnson, Rachel, Darby, Heather, Woods, Stuart, Li, Zhuhong, Priestley, Richard, Ristroph, Kurt, Biering, Scott B, EL BISSATI, KAMAL, Hwang, Seungmin, Hakim, Farida E., Dovgin, Sarah D, Lykins, Joseph D., Roberts, Lucy, Hargrave, Kerrie, Cong, Hua, Sinai, Anthony P., Muench, Stephen P., Dube, Jitender, Prud'homme, Robert, Lorenzi, Hernan A., Biagini, Giancarlo 
ORCID: https://orcid.org/0000-0001-6356-6595, Moreno, Silvia N., Roberts, Craig W., Atonyuk, Svetlana, Fishwick, Colin and McLeod, Rima
(2020)
'Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites'. Frontiers in Cellular and Infection Microbiology, Vol 10, p. 203.
|
Other (article)
Giancarlo 536546_Moreno_Manuscript.PDF - Accepted Version Available under License Creative Commons Attribution. Download (8MB) | Preview |
Abstract
Apicomplexan infections cause substantial morbidity and mortality, worldwide. New, improved therapies are needed. Herein, we create a next generation anti-apicomplexan lead compound, JAG21, a tetrahydroquinolone, with increased sp3-character to improve parasite selectivity. Relative to other cytochromeb inhibitors, JAG21 has improved solubility and ADMET properties, without need for pro-drug. JAG21 significantly reduces Toxoplasma gondii tachyzoites and encysted bradyzoites in vitro, and in primary and established chronic infections in vivo. Moreover, JAG21 treatment leads to 100% survival. Further, JAG21 is efficacious against drug-resistant Plasmodium falciparum in vitro. Causal prophylaxis and radical cure are achieved after P. berghei sporozoite infection with oral administration of a single dose (2.5mg/kg) or three days treatment at reduced dose (0.625mg/kg/day), eliminating parasitemia and leading to 100% survival. Enzymatic, binding, and co-crystallography/pharmacophore studies demonstrate selectivity for apicomplexan relative to mammalian enzymes. JAG21 has significant promise as a pre-clinical candidate for prevention, treatment and cure of toxoplasmosis and malaria.
| Item Type: | Article |
|---|---|
| Subjects: | QX Parasitology > QX 20 Research (General) QX Parasitology > QX 4 General works WC Communicable Diseases > Tropical and Parasitic Diseases > WC 725 Toxoplasmosis (General) WC Communicable Diseases > Tropical and Parasitic Diseases > WC 750 Malaria |
| Faculty: Department: | Biological Sciences > Department of Tropical Disease Biology |
| Digital Object Identifer (DOI): | https://doi.org/10.3389/fcimb.2020.00203 |
| Depositing User: | Cathy Waldron |
| Date Deposited: | 12 Jun 2020 13:20 |
| Last Modified: | 12 Aug 2020 10:29 |
| URI: | https://archive.lstmed.ac.uk/id/eprint/14275 |
Statistics
Actions (login required)
 |
Edit Item |